Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Other Non-Current Liabilities (2023 - 2025)

Historic Other Non-Current Liabilities for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $1.9 million.

  • Metagenomi's Other Non-Current Liabilities fell 3759.35% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 3759.35%. This contributed to the annual value of $2.0 million for FY2024, which is 6042.53% down from last year.
  • Latest data reveals that Metagenomi reported Other Non-Current Liabilities of $1.9 million as of Q3 2025, which was down 3759.35% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Metagenomi's Other Non-Current Liabilities ranged from a high of $5.1 million in Q4 2023 and a low of $1.9 million during Q3 2025
  • In the last 3 years, Metagenomi's Other Non-Current Liabilities had a median value of $2.6 million in 2024 and averaged $3.2 million.
  • Per our database at Business Quant, Metagenomi's Other Non-Current Liabilities plummeted by 6042.53% in 2024 and then crashed by 3759.35% in 2025.
  • Quarter analysis of 3 years shows Metagenomi's Other Non-Current Liabilities stood at $5.1 million in 2023, then plummeted by 60.43% to $2.0 million in 2024, then dropped by 4.53% to $1.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.9 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.1 million for Q1 2025.